Cota Study Suggests Some Patients Are Left Behind in Genomic Revolution

The College of American Pathologists in collaboration with the International Association for the Study of Lung Cancer, Pulmonary Pathology Society, Association for Molecular Pathology, and the LUNGevity Foundation have developed evidence-based recommendations for the testing of immunotherapy biomarkers, including programmed cell death ligand-1 and tumor mutation burden in patients with non-small cell lung carcinoma.

April 19, 2024

Vol.50 No.16

Drugs & Targets

FDA approves Alecensa for ALK-positive early-stage lung cancer

FDA approved Alecensa (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test.

April 19, 2024

Vol.50 No.16

Funding Opportunities

DOD Lung Cancer Research Program funding opportunities for FY24

The FY24 Defense Appropriations Act provides funding for the LCRP to support innovative, high-impact lung cancer research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.

April 12, 2024

Vol.50 No.15

Cota Study Suggests Some Patients Are Left Behind in Genomic Revolution

YOU MAY BE INTERESTED IN

Shanda Blackmon named director of Baylor’s Lung Institute

Surviving lung cancer focused Morhaf Al Achkar’s career on addressing health disparities

Tobacco in the tabloids: How the Weekly World News covered smoking for laughs—and the National Enquirer wouldn’t cover it at all

CAP publishes guideline for PD-L1 testing for lung cancer

FDA approves Alecensa for ALK-positive early-stage lung cancer

DOD Lung Cancer Research Program funding opportunities for FY24

Renew today!

Subscriber content

Login